Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.41 |
| ▸ | GRM5 | P41594 | 5/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864873 | 0.85 | PDK4 (0.52) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL522085 | 0.85 | PDK4 (0.52) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL16385571 | 0.84 | PDK4 (0.51) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL10036179 | 0.84 | PDK4 (0.51) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL29535433 | 0.84 | PDK4 (0.51) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL282496 | 0.83 | PDK4 (0.50) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL6365955 | 0.83 | PDK4 (0.52) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL30743124 | 0.82 | PDK4 (0.49) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL16824861 | 0.82 | PDK4 (0.49) | PDK4JAK1ALDH1A1LMNAMAPT | |
| SCHEMBL519962 | 0.82 | PDK4 (0.49) | PDK4JAK1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2015003658-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-01-15 | — | — | WO | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | PDK4 993/4885JAK1 375/4885ALDH1A1 2546/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PDK4 685/4885JAK1 4/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.